Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | GLP1R | P43220 | 10/20 | 0.48 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.48 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.45 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.45 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169051 | 0.90 | TFPI (0.53) | F2GLP1RPTH1RTFPIKEAP1 | |
| SCHEMBL30168724 | 0.86 | GLP1R (0.57) | GLP1RPTH1RMC4RVIPR1VIPR2 | |
| SCHEMBL10168659 | 0.86 | F2 (0.59) | F2GLP1RTFPIIL23R | |
| SCHEMBL10168600 | 0.86 | F2 (0.51) | F2GLP1RPTH1RTFPIMC4R | |
| SCHEMBL10168607 | 0.86 | APLNR (0.51) | F2GLP1R | |
| SCHEMBL30168773 | 0.85 | GLP1R (0.58) | GLP1RPTH1RTFPIVIPR1VIPR2 | |
| SCHEMBL29836533 | 0.85 | GLP1R (0.57) | GLP1RPTH1RVIPR1VIPR2 | |
| SCHEMBL30168685 | 0.85 | GLP1R (0.61) | GLP1RPTH1RTFPI | |
| SCHEMBL30168768 | 0.85 | GLP1R (0.61) | GLP1RPTH1RTFPI | |
| SCHEMBL30168741 | 0.85 | GLP1R (0.61) | GLP1RPTH1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | F2 4437/4885GLP1R 53/4885PTH1R 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.